Interleukin-22 Might Act as a Double-Edged Sword in Type 2 Diabetes and Coronary Artery Disease.
Fang-Chen GongJin WuPing ZhouMengyao ZhangJingning LiuYing LiuXiang LuZhengxia LiuPublished in: Mediators of inflammation (2016)
Type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD) are both characterized by chronic low-grade inflammation. The role of Th17 and its related cytokines in T2DM and CAD is unclear. Here we investigated the serum levels of five Th17-related cytokines (IL-17, IL-22, MIP-3α, IL-9, and IL-27) in T2DM, CAD, and T2DM-CAD comorbidity patients. IL-22 was found to be elevated in all three conditions. Elevated serum IL-22 was independently associated with the incidence of T2DM and CAD. Conversely, IL-22 was found to protect endothelial cells from glucose- and lysophosphatidylcholine- (LPC-) induced injury, and IL-22R1 expression on endothelial cells was increased upon treatment with high glucose and LPC. Blocking of IL-22R1 with IL-22R1 antibody diminished the protective role of IL-22. Our results suggest that IL-22 functions as a double-edged sword in T2DM and CAD and that IL-22 may be used in the treatment of chronic inflammatory diseases such as T2DM and CAD.
Keyphrases
- coronary artery disease
- endothelial cells
- type diabetes
- high glucose
- glycemic control
- oxidative stress
- chronic kidney disease
- coronary artery bypass grafting
- percutaneous coronary intervention
- cardiovascular disease
- end stage renal disease
- cardiovascular events
- blood pressure
- insulin resistance
- drug induced
- ejection fraction
- aortic valve
- blood glucose
- prognostic factors
- binding protein
- smoking cessation
- aortic stenosis